We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+28.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$484M
AUM Growth
-$276M
Cap. Flow
-$350M
Cap. Flow %
-72.29%
Top 10 Hldgs %
53.23%
Holding
55
New
5
Increased
9
Reduced
24
Closed
12

Top Buys

Rank Stock Value
1
PETX
Aratana Therapeutics, Inc.
PETX
+$13.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$7.59M
3
MYGN icon
Myriad Genetics
MYGN
+$7.31M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$5.08M
5
MTNB icon
Matinas BioPharma
MTNB
+$2.94M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$32.8M
2
DXCM icon
DexCom
DXCM
+$15.8M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.8M
4
ADMA icon
ADMA Biologics
ADMA
+$9.71M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$8.38M

Sector Composition

Rank Sector Weight
1 Healthcare 82.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
51
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-350,000
Closed -$14.4M
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-58,700
Closed -$5.71M
DOVA
53
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-351,800
Closed -$2.67M
TSRO
54
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-325,000
Closed -$24.1M
TSRO
55
DELISTED
TESARO, Inc.
TSRO
– –
-442,219
Closed -$32.8M
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Broadfin Capital held 55 positions worth $484M, down 36% from $761M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Broadfin Capital withdrew a net $350M in Q1 2019, closing 12 positions and reducing 24 holdings. Its most notable exit was TESARO, Inc., an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 56% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Myriad Genetics worth $7.97M.

  • Broadfin Capital's largest Q1 2019 buy was Myriad Genetics: 240,000 shares worth $7.97M.
  • Broadfin Capital added most to Aratana Therapeutics, Inc. in Q1 2019, an estimated $13.8M increase.
  • Broadfin Capital's biggest Q1 2019 reduction was DexCom, cutting an estimated $15.8M.
  • Broadfin Capital fully exited TESARO, Inc. in Q1 2019, selling an estimated $32.8M.
  • Broadfin Capital's ten largest holdings make up 53% of its $484M portfolio in Q1 2019.
  • Broadfin Capital opened 5 new positions and closed 12 in Q1 2019.
  • Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $484M.

Based on Broadfin Capital's 13F filing for Q1 2019, filed 15 May 2019.